Green Journals

International Approved Journals

Journal Information

Journal Title	INFLAMMATORY BOWEL DISEASES
Publisher	OXFORD UNIV PRESS INC
ISSN	1078-0998
E-ISSN	1536-4844
Database	Clarivate
Domain	Health Sciences, Life Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

From genotype-level dysfunction to variant-level causality in SLC10A2-associated bile acid malabsorption
2026-10-30
Authors: Ercan Yılmaz, Zeynep Yamancan Yılmaz
DOI: 10.1093/ibd/izag231

Handheld intestinal ultrasound and the point-of-care questions in pediatric IBD: a commentary—authors' reply
2026-10-30
Authors: Yusuke Miyatani, Alexandra Hudson, Joëlle St-Pierre et al.
DOI: 10.1093/ibd/izag199

Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom
2026-10-29
Authors: Nosheen Umar, Steven Wambua, Phil Harvey et al.
DOI: 10.1093/ibd/izag218

Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
2026-10-29
Authors: Andrea Cassinotti, Simone Saibeni, Rosanna Cannatelli et al.
DOI: 10.1093/ibd/izag229

Comparison of risankizumab and upadacitinib treatment persistence according to disease location in patients with Crohn's disease: data from the CREdIT registry
2026-10-28
Authors: Ondrej Hradsky, Dana Duricova, Milan Lukas et al.
DOI: 10.1093/ibd/izag224

Hyperuricemia aggravates acute colitis through NLRP3-associated macrophage-lineage inflammatory responses
2026-10-27
Authors: Junyi Ji, Yize Wang, Tianyu Zhou et al.
DOI: 10.1093/ibd/izag227

Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments
2026-10-26
Authors: Xiang Ma, Qingqing Shan
DOI: 10.1093/ibd/izag226

Fecal microbiota transplant in the treatment of inflammatory bowel diseases: new perspectives on delivery, mechanism, and clinical positioning
2026-10-24
Authors: Anum Javed, Despoina Chrysostomou, Julian R Marchesi et al.
DOI: 10.1093/ibd/izag219

Reply to "Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments"
2026-10-24
Authors: Milena A Gianfrancesco, Jeffrey R Curtis
DOI: 10.1093/ibd/izag220

Isolated perianal Crohn disease: the next challenge is long-term surveillance
2026-10-21
Authors: Deloshaan Subhaharan
DOI: 10.1093/ibd/izag209